精品文档---下载后可任意编辑U87-EGFRvⅢ 细胞适配子的筛选及其介导 siRNA 转运的初步应用的开题报告Title: Screening of U87-EGFRvⅢ cell aptamer and its preliminary application in mediating siRNA transportIntroduction:Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor in adults. The epidermal growth factor receptor variant III (EGFRvⅢ), a mutant form of EGFR, is overexpressed in about 50% of GBM patients and is associated with poor clinical outcomes. RNA interference (RNAi) has emerged as a promising therapeutic strategy for GBM, but the delivery of small interfering RNAs (siRNAs) to brain tumors remains a challenging problem. Aptamers are single-stranded DNA or RNA molecules that can selectively bind to target molecules with high affinity and specificity. Aptamers have been utilized as delivery vehicles for siRNA, with the potential to improve siRNA delivery into brain tumors. The purpose of this study is to screen for U87-EGFRvⅢ cell aptamers and evaluate whether they can mediate siRNA transport.Methods:1. Cell selection: The human GBM cell line U87 was chosen as the target cell due to its high expression of EGFRvⅢ.2. Aptamer selection: A cell-based systematic evolution of ligands by exponential enrichment (SELEX) protocol will be used to screen for aptamers that can bind to U87-EGFRvⅢ cells with high affinity and specificity.3. Aptamer characterization: The selected aptamers will be sequenced and analyzed for binding affinity and specificity to U87-EGFRvⅢ cells.4. SiRNA delivery: The aptamers will be evaluated for their ability to deliver siRNAs to U87-EGFRvⅢ cells in vitro. The siRNAs will target EGFRvⅢ gene expression, and the efficiency of gene knockdown will be evaluated by qRT-PCR and Western blot analysis.Expected outcomes:精品文档---下载后可任意编辑1. The successful screening for aptamers that can selectively bind to U87-EGFRvⅢ cells with high affinity and specificity.2. The characterization of the selected aptamers for their binding properties.3. The preliminary evaluation of the aptamer-mediated siRNA delivery into U87-EGFRvⅢ cells.4. The potential development of a novel aptamer-based siRNA delivery system for treating GBM.Conclusion:The development of an efficient and selective siRNA delivery system is essential for RNAi-based therapy for GBM. Aptamers have shown potential as delivery vehicles for siRNA, and this study aims to screen for U87-EGFRvⅢ cell aptamers and evaluate their ability to mediate siRNA transport. This study may provide a new strategy for improving the therapeutic efficacy of RNAi in GBM treatment.
